<DOC>
	<DOCNO>NCT00174369</DOCNO>
	<brief_summary>MEK critical member MAPK pathway involve growth survival cancer cell . PD-325901 new drug design block pathway kill cancer cell . The purpose study study effectiveness PD-325901 patient non-small cell lung cancer . PD-325901 give mouth pill twice day , CT scan do biopsy tumor blood sample take treatment examine gene affect tumor response study medication . Blood sample take measure amount drug blood .</brief_summary>
	<brief_title>MEK Inhibitor PD-325901 To Treat Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>This study terminate prematurely 23 March 2007 due safety issue ( ocular neurological toxicity observe another PD-0325901 study , A4581001 ) well lack objective response</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Histologically document nonsmall cell lung cancer metastasis ( Stage IV recurrent disease ) locally advanced ( Stage IIIB ) malignant pleural effusion expectation effect prior anticancer therapy , resolution acute toxic effect Adequate renal , liver , bone marrow function , determine within 2 week prior first treatment ECOG status &lt; =1 . Must evidence progression disease within 6 month recent prior systemic anticancer therapy . No parathyroid disorder history malignancy associate hypercalcemia No ongoing radiation therapy radiocytotoxic therapy within prior 4 week ; No immunotherapy , biologic therapy , hormonal , molecular target therapy within prior 2 week No concurrent serious infection lifethreatening illness ( unrelated tumor ) No history malignancy ( tha nonsmall cell lung cancer ) except treat curative intent skin cancer ( melanoma ) situ breast cervical cancer treat curative intent cancer evidence disease 5 year . No active seizure disorder untreated brain metastasis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
</DOC>